Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries.

[{"label":"BACKGROUND","text":"Half the global burden of cardiovascular disease (CVD) is concentrated in the Asia-Pacific (APAC) region."},{"label":"HYPOTHESIS","text":"Suboptimal control of low-density lipoprotein cholesterol (LDL-C) may play a large role in the burden of CVD in APAC and non-Western countries."},{"label":"METHODS","text":"The Acute Coronary Syndrome Management (ACOSYM) registry is a multinational, multicenter, prospective observational registry designed to evaluate LDL-C control in patients within 6\u2009months after hospitalization following an acute coronary syndrome (ACS) event across nine countries."},{"label":"RESULTS","text":"Overall, 1581 patients were enrolled, of whom 1567 patients met the eligibility criteria; 80.3% of the eligible patients were men, 46.1% had ST-elevation myocardial infarction, and 39.5% had non-ST-elevation myocardial infarction. Most (1245; 79.5%) patients were discharged on a high-intensity statin. During the follow-up, only 992 (63.3%) patients had at least one LDL-C measurement; of these, 52.9% had persistently elevated LDL-C (>70\u2009mg\/dl). The patients not discharged on a high-dose statin were more likely (OR 3.2; 95% CI 2.1-4.8) to have an LDL-C above the 70\u2009mg\/dl LDL-C target compared with those who were discharged on a high-dose statin."},{"label":"CONCLUSION","text":"Our real-world registry found that a third or more of post-ACS patients did not have a repeat LDL-C follow-up measurement. In those with an LDL-C follow-up measurement, more than half (52.9%) were not achieving a <70\u2009mg\/dl LDL-C goal, despite a greater uptake of high-intensity statin therapy than has been observed in recent evidence. This demonstrates the opportunity to improve post-ACS lipid management in global community practice."},{"copyright":"\u00a9 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC."}]